Identifying the earliest events in HIV-1 associated nephropathy via genome-wide
Identifying the earliest events in HIV-1 associated nephropathy via genome-wide
批准号:
7844482
负责人:
ALI G GHARAVI
金额:
$39.66万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-01 至 2015-02-28
关键词:
AfricanAllelesBiopsyCell LineChromosomes, Human, Pair 3ClinicalComplexComplicationCongenic MiceCongenic StrainDataDevelopmentDiseaseDisease ProgressionDissectionEarly identificationEpithelial CellsEventExhibitsFiltrationGene ExpressionGene Expression ProfileGene Expression ProfilingGenerationsGenesGeneticGenetic Predisposition to DiseaseGenetic VariationGenotypeGoalsHIV-1HumanHuman GeneticsIndividualInfectionInjuryKidneyKidney DiseasesKidney FailureLesionLinkMapsMediatingMediator of activation proteinMolecularMusMyosin Heavy ChainsNPHS2 proteinNamesPathogenesisPathologicPathway interactionsPatternPhenotypePredispositionProcessProteinsRoleStructureSusceptibility GeneTestingTherapeutic InterventionTransgenic MiceTransgenic OrganismsValidationbasecandidate validationcohortcomparativegene discoverygenetic linkage analysisgenome-widein vivoinsightmolecular phenotypemouse modelnephrinnon-muscle myosinnovelpodocyteprogramspublic health relevancestressor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goals of this project are to use a validated mouse model to dissect molecular pathways mediating he development of HIV-1 associated nephropathy (HIVAN). HIVAN is a major complication of HIV-1 infection with distinct pathologic features. This disorder is caused by HIV-1 induced dedifferentiation of glomerular podocytes, the terminally differentiated epithelial cells that maintain the structure of the kidney filtration barrier. Genetic susceptibility to HIVAN has complex determination, with significant contribution from genetic variation in the nonmuscle myosin heavy chain 9 (MYH9), a podocyte expressed gene. HIV-1 transgenic mice on the FVB/NJ genetic background recapitulate all the clinical and pathologic hallmarks of HIVAN. Using mapping cohorts between mice with contrasting susceptibility to HIVAN, we have identified three nephropathy susceptibility loci that map to chromosomes 3, 13, 4 respectively (named HIVAN1- 3) and have confirmed mapping data by examination of congenic mice that capture these intervals. By combining linkage analysis with gene expression profiling (eQTL mapping) in F2 segregants, we have also demonstrated that the murine HIVAN susceptibility loci encode transregulators of podocyte gene expression and belong to the same pathway as known human nephropathy genes (Myh9, Podocin, Nephrin, Cd2ap). The introduction of HIV-1 results in significant perturbations of the relationship between genotype and expression of specific sets of podocyte genes, indicating that HIV-1 interferes with transregulation. These considerations indicate that careful dissection of clinical and molecular phenotypes associated with each HIVAN locus and identifications of genes that demonstrate the greatest perturbation in transregulation upon HIV-1 exposure can elucidate the earliest events in the initiation of nephropathy and delineate dysregulated molecular networks mediating disease pathogenesis. To achieve these aims, we will first perform phenotypic characterization of HIVAN congenic mice to identify the contribution of each locus to initiation and progression of disease. Next we will perform analysis of glomerular transcriptome in HIV-1 transgenic congenic mice and wiltype counterparts to infer the glomerular interactome in HIVAN and discover genes that demonstrate aberrant patterns of transregulations. Finally, these genes will be validated by eQTL mapping in HIVAN segregants, by functional studies in human podocytes and ultimately, by generation of transgenic lines that will confirm findings. Identification of molecular mediators of HIVAN is expected to provide significant insight into the pathogenesis of disease and provide novel targets for therapeutic intervention.
PUBLIC HEALTH RELEVANCE: HIV-1 associated nephropathy is a major complication of HV-1 infection and a significant cause of kidney failure worldwide. Identification of molecular mediators of HIVAN is expected to provide significant insight into the pathogenesis of disease and provide novel targets for therapeutic intervention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Columbia/Cornell/Harlem Hospital Precision Medicine Initiative HPO
-
批准号:9525197
-
项目类别:
-
资助金额:$212.9万
-
财政年份:2016
-
负责人:ALI G GHARAVI
-
依托单位:
Columbia/Cornell/Harlem Hospital Precision Medicine Initiative HPO
-
批准号:9228787
-
项目类别:
-
资助金额:$446.13万
-
财政年份:2016
-
负责人:ALI G GHARAVI
-
依托单位:
Columbia GENIE (GENomic Integration with Ehr)
-
批准号:9134799
-
项目类别:
-
资助金额:$85.98万
-
财政年份:2015
-
负责人:ALI G GHARAVI
-
依托单位:
Columbia GENIE (GENomic Integration with Ehr)
-
批准号:9896294
-
项目类别:
-
资助金额:$70.74万
-
财政年份:2015
-
负责人:ALI G GHARAVI
-
依托单位:
Columbia GENIE (GENomic Integration with Ehr)
-
批准号:8968053
-
项目类别:
-
资助金额:$85.95万
-
财政年份:2015
-
负责人:ALI G GHARAVI
-
依托单位:
Human genetic approaches to lower urinary tract phenotypes
-
批准号:10297545
-
项目类别:
-
资助金额:$22.85万
-
财政年份:2014
-
负责人:ALI G GHARAVI
-
依托单位:
The Host Genome and the Urinary Microbiome in UTI and GU Structural Defects
-
批准号:10022308
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2014
-
负责人:ALI G GHARAVI
-
依托单位:
Human genetic approaches to lower urinary tract phenotypes
-
批准号:10700954
-
项目类别:
-
资助金额:$24.21万
-
财政年份:2014
-
负责人:ALI G GHARAVI
-
依托单位:
Human genetic approaches to lower urinary tract phenotypes
-
批准号:10487492
-
项目类别:
-
资助金额:$23.36万
-
财政年份:2014
-
负责人:ALI G GHARAVI
-
依托单位:
The Columbia PCC for CureGN: the Cure Glomerulonephropathy network
-
批准号:10212101
-
项目类别:
-
资助金额:$16.2万
-
财政年份:2013
-
负责人:ALI G GHARAVI
-
依托单位:
Advancing Clinical Research in Primary Glomerular Diseases (UM1)
-
批准号:8924174
-
项目类别:
-
资助金额:$6.21万
-
财政年份:2013
-
负责人:ALI G GHARAVI
-
依托单位:
Advancing Clinical Research in Primary Glomerular Diseases (UM1)
-
批准号:8733168
-
项目类别:
-
资助金额:$80.52万
-
财政年份:2013
-
负责人:ALI G GHARAVI
-
依托单位:
Advancing Clinical Research in Primary Glomerular Diseases (UM1)
-
批准号:8914614
-
项目类别:
-
资助金额:$80.52万
-
财政年份:2013
-
负责人:ALI G GHARAVI
-
依托单位:
Advancing Clinical Research in Primary Glomerular Diseases (UM1)
-
批准号:8628397
-
项目类别:
-
资助金额:$53.95万
-
财政年份:2013
-
负责人:ALI G GHARAVI
-
依托单位:
The Columbia PCC for CureGN: the Cure Glomerulonephropathy network
-
批准号:10165699
-
项目类别:
-
资助金额:$100.07万
-
财政年份:2013
-
负责人:ALI G GHARAVI
-
依托单位:
The Columbia PCC for CureGN: the Cure Glomerulonephropathy network
-
批准号:10414152
-
项目类别:
-
资助金额:$94.38万
-
财政年份:2013
-
负责人:ALI G GHARAVI
-
依托单位:
The Columbia PCC for CureGN: the Cure Glomerulonephropathy network
-
批准号:10691635
-
项目类别:
-
资助金额:$59.79万
-
财政年份:2013
-
负责人:ALI G GHARAVI
-
依托单位:
Advancing Clinical Research in Primary Glomerular Diseases (UM1)
-
批准号:9310239
-
项目类别:
-
资助金额:$80.52万
-
财政年份:2013
-
负责人:ALI G GHARAVI
-
依托单位:
Advancing Clinical Research in Primary Glomerular Diseases (UM1)
-
批准号:9130499
-
项目类别:
-
资助金额:$7.9万
-
财政年份:2013
-
负责人:ALI G GHARAVI
-
依托单位:
Discovery and fine mapping of susceptibility loci for IgA nephropathy
-
批准号:8719093
-
项目类别:
-
资助金额:$45.77万
-
财政年份:2012
-
负责人:ALI G GHARAVI
-
依托单位:
海外基金